Autophagy as a therapeutic target in pancreatic cancer

Area of Science:

• Oncology
• Cellular Biology
• Cancer Therapeutics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is marked by early metastasis and resistance to therapies.
• Common genetic alterations like KRAS and TP53 mutations in PDAC have limited targeted treatment options.
• Autophagy, a cellular degradation process, is upregulated in PDAC and linked to treatment resistance.

Purpose of the Study:

• To review preclinical data on autophagy's role in PDAC.
• To examine clinical trial results of autophagy-modulating agents in PDAC.
• To explore potential therapeutic strategies combining autophagy inhibitors with other pathway inhibitors.

Main Methods:

• Review of existing preclinical studies on autophagy in PDAC.
• Analysis of clinical trial data for agents targeting autophagy in pancreatic cancer.
• Exploration of combined therapeutic approaches, including MEK/MAPK pathway inhibitors.

Main Results:

• Autophagy is upregulated in PDAC and contributes to resistance against chemotherapy and targeted treatments.
• Preclinical studies show promise in combining autophagy inhibitors with MEK/MAPK pathway inhibitors in KRAS-driven cancers.
• Clinical trials investigating autophagy modulators in PDAC are ongoing, with preliminary data guiding further research.

Conclusions:

• Autophagy represents a potential therapeutic target for pancreatic cancer.
• Combining autophagy inhibition with other targeted therapies, particularly in KRAS-mutated PDAC, warrants further investigation.
• Continued research into the molecular mechanisms of autophagy in PDAC is crucial for developing effective treatments.